midterm 2: drug use + access + role of pharmaceutical industry ദ്ദി ༎ຶ‿༎ຶ )

0.0(0)
Studied by 2 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/39

encourage image

There's no tags or description

Looks like no tags are added yet.

40 Terms

1
New cards

What are the most visible treatments in medical care?

Pharmaceuticals

2
New cards

What is one reason consumers are so familiar with pharmaceuticals?

DTCA (direct-to-consumer advertising), simplicity of drugs

3
New cards

What are the three meanings of the word Pharmakon? What language does it originate from?

Originates from Greek and is the greek word for drug; its three meanings are “remedy,” “poison,” and “magical charm.”

4
New cards

What is using a medication for a condition that is not FDA-approved known as?

Unapproved/”off-label” use

5
New cards

What is medicalization? What are some examples?

Defines a personal or social problem as a medical condition that necessitates treatment. Examples include treatment of articulation disorder, obesity, and ADHD.

6
New cards

Consumer beliefs regarding medications are often very (similar/different) from the beliefs held by health care professionals.

Different

7
New cards

What are some factors influencing prescriber behavior?

Education

Colleagues or other healthcare providers

Demands by consumers and society

Promotional activities by drug manufacturers

8
New cards

Who determines which drugs are allowed to be sold and prescribed in the US?

FDA

9
New cards

Who determines which drugs are categorized as prescription or non-prescription?

FDA

10
New cards

Which acts are used by the FDA to control the development and manufacturing of pharmaceuticals?

Food, Drug, and Cosmetic Act (1938)

Public Health Service Act (1944)

11
New cards

Which act guides how the FDA regulates small molecules and hormones?

Food, Drug, and Cosmetic Act (1938)

12
New cards

Which act regulates biological drugs (much larger and more complex than small-molecule drugs)?

Public Health Service Act (1944)

13
New cards

What organization monitors the safety of the nation’s blood supply?

FDA

14
New cards

Once a drug is approved for the market, the FDA has full power to determine how it is ultimately used.

False; it has few powers

15
New cards

What are the steps in the drug development process?

Discovery research

Preclinical testing

Clinical testing

NDA submittal for approval

16
New cards

When does a drug manufacturer have to submit an IND application to the FDA?

After pre-clinical (animal) testing and before clinical testing

17
New cards

What does IND stand for in the drug manufacturing process?

Investigational New Drug application

18
New cards

How many phases are there in clinical testing?

Four

19
New cards

Around how many compounds are evaluated for each one drug that is approved by the FDA for marketing?

5,000-10,000 (slide with table says 5,000 so go w that)

20
New cards

Around how many compounds enter clinical trials for each one drug that is approved by the FDA for marketing?

5

21
New cards

How long does the drug development process take?

Around 15 years

22
New cards

Around how long does the FDA review the NDA before approval?

1.5 years

23
New cards

Who are the subjects in phase I clinical trials? What are phase I’s goals, and how long does it last?

<100 healthy volunteers; determine safety and dosage; 1-1.5 years

24
New cards

Who are the subjects in phase II clinical trials? What are phase II’s goals, and how long does it last?

100-500 (less than 300 according to slides) patient volunteers (with target disease/symptom); safety and efficacy in treating disease/symptom as well as potential side effects; 2 years

25
New cards

Who are the subjects in phase III clinical trials? What are phase III’s goals, and how long does it last?

1000-5000 (less than 3000 according to slides) patient volunteers (with target disease/symptom); confirm safety, dosage, and effectiveness and monitor long-term adverse effects; 3-3.5 years

26
New cards

Which department of the FDA reviews the NDA?

Center for Drug Evaluation and Research (CDER)

27
New cards

What is phase IV of clinical trials? What does it monitor for?

Phase IV refers to post-marketing surveillance after a drug has entered the market; it continues to monitor the drug’s safety and efficacy and monitor for side effects that may have been missed in earlier trials

28
New cards

What is an sNDA?

Stands for supplemental NDA; submitted to the FDA if firms wish to alter a drug’s ingredients, dosage, manufacturing, or labeling

29
New cards

What is an abbreviated NDA, and what is it used for?

An abbreviated NDA is a shortened form of the NDA that does not require any pre-clinical or clinical data. It is used for generic drug manufactureres to demonstrate that their product is bioequivalent with the brand-name equivalent drug.

30
New cards

What is bioequivalence?

When a drug has the same rate and extent of absorption into the bloodstream as the brand drug

31
New cards

What is pharmaceutical equivalence?

Drugs with the same active ingredient(s), dosage form, and strength (colors, taste, and other features may vary)

32
New cards

What are the two aspects of therapeutic equivalence?

Pharmaceutical equivalence + bioequivalence = therapeutic equivalence

33
New cards

What ultimately determines the price of a drug?

Manufacturer’s cost + profit

Wholesaler’s cost + profit

Retailer’s cost + profit

Discounts

Supply and demand

34
New cards

(T/F) Generally, it is legal to purchase prescription drugs in another country for use in the U.S.

False; it is illegal (there are some exceptions)

35
New cards

(T/F) With FDA approval, drugs developed and produced outside the U.S. can be sold in the U.S. as prescription drugs.

True

36
New cards

Over __ percent of drugs sold in the developing world are counterfeit.

30%

37
New cards

What are some benefits and downsides of foreign clinical trials?

Benefits:

  • Allows for diverse populations in trials

Downsides:

  • FDA not equipped to inspect many foreign trial sites

  • Can be dificult to tell why patient outcomes differ between sites

  • Each site may have different standards so data interpretation is limited due to lack of standardization


38
New cards

What act regulates IPRs for small-molecule drugs? How long does data exclusivity and patent protection last?

Hatch-Waxman Act of 1984; 5 years data exclusivity (from FDA approval) and 20 years patent

39
New cards

What act regulates IPRs for biologics? How long does data exclusivity and patent protection last?

Patent Protection and Affordable Care Act (PPACA) of 2010; 12 years data exclusivity (from FDA approval) and 20 years patent

40
New cards

Which drug type requires new (but limited) clinical trials for generics/biosimilars: small-molecule drugs or biologic drugs?

Biologic drugs